Healios K.K (TYO:4593) has agreed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the clinical data package for conditional approval of MultiStem for Acute Respiratory Distress Syndrome, according to a Wednesday filing with the Tokyo Stock Exchange.
The approval will be based on Phase 2 trial results, with future Phase 3 data from the US as confirmatory support.
MultiStem is a regenerative medicine targeting ARDS, ischemic stroke, and trauma, and has received FDA Fast Track and RMAT designations.
Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.